A clinical study of LY 01018
Latest Information Update: 06 Jul 2020
At a glance
- Drugs LY 01018 (Primary)
- Indications Cancer; Solid tumours
- Focus Adverse reactions
Most Recent Events
- 06 Jul 2020 New trial record
- 23 Jun 2020 According to a Luye Pharma Group media release, the company has received formal acceptance of clinical trial application from the Center for Drug Evaluation of the National Medical Products Administration in China for this trial and expects to begin this trial soon.